ExonHit SpliceArray products available on Affymetrix microarray platform

By Lisa Kerner

Erie, Pa., April 18 - ExonHit Therapeutics said a number of its SpliceArray products are now available on the Affymetrix microarray platform as a result of the supply and provider agreement between ExonHit and Affymetrix signed last October.

The SpliceArrays available on the Affymetrix GeneChip platform include ExonHit's SpliceArrays for GPCR, Ion Channel, nuclear receptors and apoptosis pathways, with custom arrays available, according to a company news release.

SpliceArrays are a new generation of microarrays that resolve the expression of genes at the level of their alternatively spliced transcripts, the company said.

ExonHit said its SpliceArray content and probe meet the need for robust and accurate tools to fully interrogate the complete transcriptome for a better understanding of diseases.

"This move is a step towards our goal of offering our SpliceArray technology to the marketplace on several platforms, thus providing maximum flexibility to our customers," said Bruno Tocqué, president of ExonHit's management board, in the release.

"Our SpliceArray products are now available on both Agilent and Affymetrix microarray platforms, the two main platforms used routinely in the fields of ongoing research, drug discovery and diagnostics."

ExonHit is a drug and diagnostic discovery company located in Paris.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.